



DRUGS AND CHEMICALS LIMITED

Registered Office :
815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA).
Ph. : +91-265-2991021 / 2991022

Email : admin@pardrugs.com

CIN No. : L24117GJ1999PLC035512

www.pardrugs.com

PAR/CS/NSE/2021-22/70

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Date: 10/02/2022

Symbol - PAR, ISIN: INE04LG01015

Subject: Investors Presentation

Ref.: Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to above captioned subject and pursuant Regulation 30 read with Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby attached our latest Investors Presentation.

You are requested to kindly take note on your record.

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED

(Mr. Falgun V. Savani)

Managing Director

DIN: 00198236

Encl: As above



9M/Q3-FY22 Earnings Presentation

Company Overview




Company Overview



- Promoted by Mr. Falgun Savani and Mr. Jignesh Savani, Par Drugs and Chemicals Limited (PDCL) was founded in 1982 and is engaged in the development and manufacturing of APIs.



- The Company today manufactures more than 28 different products and all the requisite grades as available in the market. The product portfolio presently comprises of 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.
- Currently, the company owns and operates a manufacturing facility at Bhavnagar in Gujarat with an annual capacity of 9,700 MT.
- The company is the largest manufacturer of Magnesium Hydroxide, Sucralfate and Magnesium Trisilicate in India.
- Company's key customers include Essential Drugs Company Ltd., Pfizer Ltd., United Phosphorus Ltd., Cipla Ltd., etc.
- PDCL exports its products to approximately 16 countries, including Germany, the United Kingdom, Bangladesh, Iran, and U.A.E etc.
- APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

Operational Revenues (INR Mn)



Business Mix (9M-FY22)

International Sales





Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. The product portfolio presently comprises 18 APIs and 10 Fine Chemicals which are marketed domestically and exported.



Global Presence: The Company is operating both in domestic and export markets. The export products are to approximately 16 countries, including Germany, United Kingdom, Bangladesh, Iran, and U.A.E, Indonesia, Japan, South Korea, etc.



Experienced Promoters: Led by qualified and experienced Promoters and key managerial personnel, who we believe have extensive knowledge and understanding of the APIs business environment and have the expertise and vision to organically scale up the business.



Robust Chemistry Capabilities: A research driven Company with R&D efforts focused on developing processes and achieving process improvements and production cost efficiencies.



Diversified Customer base: Catering to more than 191 customers through dealers/agents worldwide.



Established Sales and distribution network: Comprising of more than 40 dealers and distribution network is spread globally comprising of 13 agents.



Cash Rich Company: The company is a net debt free and generates free cash flow. They plan its expansions through internal accruals.

The image features a background of financial documents with a bar chart, a pie chart, and a pair of glasses. A large blue circle on the left contains the text 'FINANCIAL & OPERATIONAL HIGHLIGHTS'. A yellow circle is positioned above the blue one. The bar chart shows monthly data from February to December with values ranging from 10.85 to 31.08. The pie chart shows segments with values 22 and 29.

FINANCIAL & OPERATIONAL HIGHLIGHTS



Q3-FY22 Financial Highlights


Revenue INR 169 Mn	EBITDA INR 35 Mn	EBITDA Margin 20.71%
PAT INR 21 Mn	PAT Margin 12.43%	Diluted EPS INR 1.72

9M-FY22 Financial Highlights

Revenue INR 530 Mn	EBITDA INR 117 Mn	EBITDA Margin 22.08%
PAT INR 68 Mn	PAT Margin 12.83%	Diluted EPS INR 5.52

Operational Highlights

- Revenue growth was impacted in the quarter as the increase in finished goods realisations, on account of rising input costs on Raw Materials, Fuel (Coal) and Transportation, could not be immediately passed on to customers.
- Gradual improvement in revenue growth levels are expected once the raw material costs stabilise, and subsequently margins also should return back to normalised levels.
- Sales from Exports and its contribution to overall sales has seen good increase in the quarter and on a YTD basis.



9M/Q3-FY22 Financial Overview



Quarterly Financial Performance

Income Statement (INR Mn)	Q3-FY22	Q3-FY21	Y-o-Y	Q2-FY22	Q-o-Q
Income from Operations	169	163	3.7%	196	(13.8)%
Total Expenses	134	124	8.1%	156	(14.1)%
EBITDA	35	39	(10.3)%	40	(12.5)%
<i>EBITDA Margin</i>	<i>20.71%</i>	<i>23.93%</i>	<i>(322) bps</i>	<i>20.41%</i>	<i>30 bps</i>
Finance Cost	1	-	NA	2	(50.0)%
Depreciation	8	6	33.3%	8	NA
Other Income	1	-	NA	-	NA
Profit before Extra Ordinary Items	27	33	(18.2)%	30	(10.0)%
Extraordinary items	-	-	NA	-	NA
Profit Before Tax	27	33	(18.2)%	30	(10.0)%
Tax	6	12	(50.0)%	8	(25.0)%
Profit after tax	21	21	NA	22	(4.5)%
<i>PAT Margin</i>	<i>12.43%</i>	<i>12.88%</i>	<i>(45) bps</i>	<i>11.22%</i>	<i>121 bps</i>
Other Comprehensive Income	-	-	NA	-	NA
Total Comprehensive Income	21	21	NA	22	(4.5)%
Diluted EPS (INR)	1.72	3.39	(49.3)%	1.8	(4.4)%

YTD Financial Performance

Income Statement (INR Mn)	9M-FY22	9M-FY21	Y-o-Y
Income from Operations	530	445	19.1%
Total Expenses	413	328	25.9%
EBITDA	117	117	NA
<i>EBITDA Margin</i>	<i>22.08%</i>	<i>26.29%</i>	<i>(421) bps</i>
Finance Cost	4	4	0.0%
Depreciation	24	21	14.3%
Other Income	2	1	100.0%
Profit before Extra Ordinary Items	91	93	(2.2)%
Extraordinary items	-	-	NA
Profit Before Tax	91	93	(2.2)%
Tax	23	21	9.5%
Profit after tax	68	72	(5.6)%
<i>PAT Margin</i>	<i>12.83%</i>	<i>16.18%</i>	<i>(335) bps</i>
Other Comprehensive Income	-	-	NA
Total Comprehensive Income	68	72	(5.6)%
Diluted EPS (INR)	5.52	11.69	(52.8)%

Historical Income statement


Income Statement (INR Mn)	FY19	FY20	FY21	9M-FY22
Income from Operations	463	558	607	530
Total Expenses	381	464	448	413
EBITDA	82	94	159	117
<i>EBITDA Margin</i>	<i>17.71%</i>	<i>16.85%</i>	<i>26.19%</i>	<i>22.08%</i>
Finance Cost	20	8	6	4
Depreciation	30	27	28	24
Other Income	1	1	2	2
Profit before Extra Ordinary Items	33	60	127	91
Extraordinary items	-	-	(20)	-
Profit Before Tax	33	60	147	91
Tax	8	12	31	23
Profit after tax	25	48	116	68
<i>PAT Margin</i>	<i>5.40%</i>	<i>8.60%</i>	<i>19.11%</i>	<i>12.83%</i>
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	25	48	116	68
Diluted EPS (INR)	5.60	7.75	18.87	5.52

Balance Sheet


EQUITIES & LIABILITIES (INR Mn)	FY20	FY21	H1-FY22	ASSETS (INR Mn)	FY20	FY21	H1-FY22
Shareholder Funds	406	523	569	Non Current Assets	359	352	352
(A) Equity Share Capital	61	62	123	(A) Fixed Assets			
(B) Reserves & Surplus	345	461	446	(i) Tangible Assets	344	299	344
				(ii) Capital work-in-progress	7	45	-
Non-current Liabilities	87	82	78	(B) Non Current Investments	1	-	-
(A) Long Term borrowings	46	44	40	(C) Long Term Loans & Advances	7	8	8
(B) Deferred Tax Liabilities (net)	37	34	34				
(C) Long term Provisions	4	4	4				
Current Liabilities	108	159	89	Current Assets	242	412	384
(A) Short term borrowings	-	32	-	(A) Inventories	29	30	30
(B) Trade Payables	62	67	57	(B) Trade Receivables	124	125	141
(C) Other Current Liabilities	27	25	13	(C) Cash & cash equivalents	74	212	179
(D) Short term Provisions	19	35	19	(D) Short Term Loans & Advances	6	-	-
				(E) Other Current Assets	9	45	34
GRAND TOTAL - EQUITIES & LIABILITES	601	764	736	GRAND TOTAL – ASSETS	601	764	736

Financial Highlights


Operational Revenue (INR Mn)




EBITDA (INR Mn) & EBITDA Margins (%)



PAT (INR Mn) & PAT Margins (%)




RoCE & RoE



Net Debt to Equity Ratio (x)




Net Worth (INR Mn)



Price Data (31 st December, 2021)	INR
Face Value	10.0
Market Price	201.25
52 Week High/Low	310.60/58.45
Market Cap (Mn)	2,476.3
Equity Shares Outstanding (Mn)**	12.3
1 Year Avg Trading Volume ('000)	32.8

Shareholding Pattern as on 31st December, 2021



** Issue of Bonus shares in the ratio of 1:1 on 30th April, 2021

Par Drugs and Chemicals Limited:

The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from, this Presentation is expressly excluded. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal
Valorem Advisors

Tel: +91-22-4903-9500

Email: pardrugs@valoremadvisors.com



Thank
You